| Product Code: ETC9469294 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sri Lanka Gastrointestinal Diseases Drug Development Market Overview |
3.1 Sri Lanka Country Macro Economic Indicators |
3.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, 2021 & 2031F |
3.3 Sri Lanka Gastrointestinal Diseases Drug Development Market - Industry Life Cycle |
3.4 Sri Lanka Gastrointestinal Diseases Drug Development Market - Porter's Five Forces |
3.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Molecular Targets, 2021 & 2031F |
3.7 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Marketed Drugs, 2021 & 2031F |
3.8 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Clinical Trials, 2021 & 2031F |
3.9 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Sri Lanka Gastrointestinal Diseases Drug Development Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal diseases in Sri Lanka |
4.2.2 Growing awareness about the importance of early diagnosis and treatment |
4.2.3 Advancements in drug development technologies and research in the country |
4.3 Market Restraints |
4.3.1 Limited healthcare infrastructure and resources in Sri Lanka |
4.3.2 High cost associated with drug development and treatment |
4.3.3 Regulatory challenges and delays in drug approval processes |
5 Sri Lanka Gastrointestinal Diseases Drug Development Market Trends |
6 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Types |
6.1 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Gastroenteritis, 2021- 2031F |
6.1.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Inflammatory Bowel Disease (IBD), 2021- 2031F |
6.1.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Irritable Bowel Syndrome, 2021- 2031F |
6.1.6 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Molecular Targets |
6.2.1 Overview and Analysis |
6.2.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sodium Transporter NHE3 Inhibitor, 2021- 2031F |
6.2.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sphinogosine-1-Phosphate Receptor Functional Antagonist, 2021- 2031F |
6.2.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Tumor Necrosis Factor (TNF) Blocker, 2021- 2031F |
6.2.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Marketed Drugs |
6.3.1 Overview and Analysis |
6.3.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.3.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.3.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Mesalazine, 2021- 2031F |
6.3.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Clinical Trials |
6.4.1 Overview and Analysis |
6.4.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Etrolizumab, 2021- 2031F |
6.4.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By SHP647, 2021- 2031F |
6.4.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ABX464, 2021- 2031F |
6.4.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ASP3291, 2021- 2031F |
6.4.6 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Sri Lanka Gastrointestinal Diseases Drug Development Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Injectable, 2021- 2031F |
6.6 Sri Lanka Gastrointestinal Diseases Drug Development Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
7 Sri Lanka Gastrointestinal Diseases Drug Development Market Import-Export Trade Statistics |
7.1 Sri Lanka Gastrointestinal Diseases Drug Development Market Export to Major Countries |
7.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Imports from Major Countries |
8 Sri Lanka Gastrointestinal Diseases Drug Development Market Key Performance Indicators |
8.1 Number of clinical trials conducted for gastrointestinal diseases drugs in Sri Lanka |
8.2 Investment in research and development for gastrointestinal drugs in the country |
8.3 Number of partnerships and collaborations between local and international pharmaceutical companies for drug development in Sri Lanka |
9 Sri Lanka Gastrointestinal Diseases Drug Development Market - Opportunity Assessment |
9.1 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Molecular Targets, 2021 & 2031F |
9.3 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Marketed Drugs, 2021 & 2031F |
9.4 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Clinical Trials, 2021 & 2031F |
9.5 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Sri Lanka Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Sri Lanka Gastrointestinal Diseases Drug Development Market - Competitive Landscape |
10.1 Sri Lanka Gastrointestinal Diseases Drug Development Market Revenue Share, By Companies, 2024 |
10.2 Sri Lanka Gastrointestinal Diseases Drug Development Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here